Martin Reck, MD, PhD, Lung Clinic Grosshansdorf, Grosshansdorf, Germany, shares the results of the Phase III JAVELIN trial (NCT02576574), the Phase II the Phase II PRIMUS (NCT02564380) study, the Phase IB/II NintNivo (NCT04046614) trial, the Phase III IMpower010 (NCT02486718) trial and the Phase II NADIM (NCT03838159) trial. The JAVELIN study assessed avelumab versus chemotherapy for first-line treatment of advanced PD-L1-postive non-small cell lung cancer (NSCLC) and did not meet the primary endpoint of overall-survival (OS) or progression-free survival (PFS). The PRIMUS trial assessed maintenance therapy with pembrolizumab versus placebo in patients with squamous cell carcinoma who had received first-line chemotherapy. The trial was closed early due to slow accrual, however, a clear signal in efficacy favored maintenance treatment with pembrolizumab. The NintNivo trial investigated nintedanib with nivolumab which demonstrated a median OS of more than 12 months. The IMpower010 trial explored atezolizumab in resected patients following adjuvant chemotherapy which showed a significant improvement in OS in PD-L1-positive patients. Finally, the NADIM II investigated neoadjuvant chemoimmunotherapy versus chemotherapy in patients with stage III NSCLC, which saw a significant prolongation of OS and PFS in patients who received the neoadjuvant chemoimmunotherapy. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

свернуть